Company: LDWY
Filing Date: 2025-08-28
Form Type: 10-KT
Source: 0001558370-25-011807
Chunk: 60

Company: LENDWAY, INC.
Filing Date: 2025-08-28
Form: 10-KT
Chunk 60
---
-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as by assumptions regarding several complex and subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. During the six months ended June 30, 2025, and calendar years 2024 and 2023, the Company issued zero, 27,000, and zeroshares of restricted stock under its 2018 equity incentive plan, respectively. For calendar year 2024, the shares underlying the awards were assigned a grant date fair value of $ 5.64per share, based on the stock price on the date of grant, and are scheduled to vest over three years. The Company recorded total stock-based compensation expense of $ 39,000, $ 60,000, and $ 44,000for the six months ended June 30, 2025 and calendar years 2024 and 2023, respectively. Net Income (Loss) per Share.Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average shares outstanding and excludes any dilutive effects of stock options and restricted stock units and awards. Diluted net income (loss) per share gives effect to all diluted potential common shares outstanding during the year. In determining diluted net income (loss) per share, the Company considers whether the result of the incremental shares would be antidilutive. During the six months ended June 30, 2025, there were 1,000incremental shares that were excluded from the computation of diluted weighted average shares outstanding because their inclusion would have been anti-dilutive. In calendar years 2024 and 2023, the Company had a net loss from continuing operations. Accordingly, the result of potentially dilutive securities was determined to be anti-dilutive. At June 30, 2025 and December 31, 2024, nooptions were outstanding. At December 31, 2023, options to purchase 1,000shares of common stock with a weighted average exercise price of $ 15.54were outstanding and determined to be antidilutive.

<div align='center'>F-14</div>

#### Weighted average common shares outstanding for the six months ended June 30, 2025, and calendar years 2024 and 2023 were as follows:​​​​​​​​​Six Months Ended